We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CIPLA TEDUGLUTIDE, REVACIP Cipla Australia Pty Ltd
Product name
CIPLA TEDUGLUTIDE, REVACIP
Sponsor
Accepted date
Mar-2025
Active ingredients
teduglutide
Proposed indication
Cipla Teguglutide is used to treat adults and children (2 years and older) with short bowel syndrome who need parenteral nutrition (when nutrients are infused directly into the bloodstream). Patients should be stable on their parenteral support for at least 4 weeks before starting teduglutide therapy.
Application type
A (new medicine)
Publication date
Mar-2025